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Abstract: Urothelial carcinomas (UC) are the most common cancer type of the urinary system. The early diagnosis and treatment
of UC are very important.The aim of this study was to evaluate the importance of the nuclear matrix protein 22 (NMP22) in early
diagnosis of UC and to present its variation in cystitis and urothelial dysplasia (UD).
Twenty patients with UC, 20 patients with UD and 20 patients with cystitis diagnosed by urinary cytological examination were
enrolled in this study. In addition, 20 healthy people constituted the control group. Urine samples were collected from all patients
and control subjects for NMP22 measurement and cytology. Those who were diagnosed with cytological malignancy were also
histologically evaluated for accuracy. Additionally, the NMP22 levels of all participants were measured by ELISA.
When compared according to the cytologic results, the NMP22 levels in the UC group were found significantly higher compared to
those having UD, cystitis and control group (P < 0.05). No statistically significant difference was found between other groups.
It has been concluded that NMP22 can be used in the early diagnosis and determination of recurrences in UC. However, as the
NMP22 level may be increased by other factors such as UD, cystitis, bladder stones and non-urothelial carcinomas of bladder, it is
suggested urinary cytology that showed be jointly used with NMP22 measuring.
Key Words: Nuclear matrix protein 22, urinary cytology, urothelial carcinoma, urothelial dysplasia, cystitis

Introduction
The bladder urothelial carcinomas (UC) are those
which appear in men and women at the 4th and 8th
frequency, respectively of all human carcinomas.
Approximately 70-80% of these carcinomas are localized
in the epithelium or only invasive in the lamina propria.
The superficial UC are treated by transurethral resection
or fulguration. However, a large portion (50-75%) of
them reoccur in a different location within five years.
Most of these recurrences take place in the first year (14). The existence of recurrences in UC of bladder is
controlled by cystoscopy and urine cytology every 3
months during the first two years after diagnosis. In low
grade papillary UC, cystoscopy is considerably invasive.

More sensitive, especially quantitative and objective noninvasive techniques are required to determine low grade
tumors (1,2,5).
Nuclear matrix protein (NMP) was first identified by
Berezney and Coffey in the nucleus of rat liver cell (6).
Nuclear matrix is composed of insoluble nuclear lamina,
pore complexes, residual nucleolus, and internal
ribonucleoprotein network (6,7). By determining the
three-dimensional structure of the nucleus, the nuclear
matrix has an important role in DNA replication and
transcription, RNA formation, and gene organization and
expression (3,4,6,8,9). Nuclear matrix proteins are a new
class of tumor markers which have increased the efficacy
of detection and treatment of cancer (10).
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NMP22 levels in the urine of patients with bladder
cancer are estimated to be at least 25 times higher than
the urine of the normal subjects (9). It has been indicated
that NMP22, which is spontaneously determined by
ELISA method, is an important indicator especially in
rapid recurrences following operation (3-5,8).
In this study we aimed to investigate the significant
value of NMP22 in UC, urothelial dysplasia (UD) and
cystitis, which are diagnosed by urine cytology.

processed by cytospin from urine samples. Some of these
samples which were prepared with cytospin were then
fixed by alcohol and stained by Papanicolaou and the
other slides were dried in air and stained by May
Grunwald Giemsa. The samples were then examined
using a Leica MMLB (Germany) microscope by the same
pathologist.
Kruskal-Wallis test and Mann-Whitney U test were
used for statistical analysis and a threshold value as P <
0.05 was considered to be statistically significant.

Materials and Methods
A total of 60 patients (46 men- 76.67%, 14 women23.33%): 20 UC (15 men- 75%, 5 women- 25%), 20
UD (13 men- 65%, 7 women- 35%) and 20 cystitis (17
men- 85%, 3 women- 15%) who were diagnosed by
urine cytology at Fırat University Firat Health Centre
Urology Policlinics, and 20 healthy people (14 men- 70%,
6 women- 30%) were enrolled in this study. The patient
and control group subjects were informed on the study
and written consent was obtained.
Urine samples were collected between 08:00 and
12:00 a.m. and stabilized immediately for NMP22
measurement and cytology. Those diagnosed as
malignant by cytology were also proved so
histopatologically. Additionally, the NMP22 levels of all
participants were measured by ELISA (Matritech NMP22
test kit Newton, MA-USA) method. Preparations were

Results
Mean age of the cases were found to be 56 ± 14
years in UC, 50 ± 13 years in UD, 50 ± 15 in cystitis
groups, and 49 ± 11 in healthy person.
It was found that NMP22 levels of patients, who were
cytologically diagnosed as malignant, were significantly
higher than those patients with UD and urinary system
infection, and control group (P < 0.05). No significant
differences were seen between the other groups (p>
0.05). The mean ages and the values of NMP22 levels of
all participants are given in the Table.
We found that the sensitivity and specificity of this
test were 44% and 56%, respectively. The cut off value
was 2.60 U/mL.These results were given in Figure.

Table. Urinary NMP22 values (Units/mL).

Groups

n

Age

NMP22

(years;

(Mean)

Mean ± SD)

(U/mL)

SD

SE

Max

Min

Controls

20

49 ± 11

5.02

5.28

1.32

16.90

0.50

Cystitis

20

50 ± 15

22.17

33.90

6.41

120.30

0.20

UD

20

50 ± 13

39.58

104.70

31.58

354.12

0.90

UC

20

56 ± 14

111.50*

142.90

41.27

392.10

1.50

Total

80

51 ± 14

36.90

83.01

10.14

392.10

0.20

*: P < 0.05
UD: urothelial dysplasia, UC: urothelial carcinoma, SD: standard deviation, SE: standard error,
Max: maximum, Min: minimum
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1,0

gender and smoking. It has been determined that NMP22
increases in prostate, colon, breast, kidney, bone, and
other tissues or in occult extravesical neoplasm. However,
the increase of NMP22 in these conditions is lower
compared to the increase in UC. It may also increase
following systemic chemotherapy used for other
malignancies (5,7,12).
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Figure. Sensitivity and specificity calculation according to ROC curve.

Discussions
In order to follows recurrency of tumor, in patients
with UC cystoscopy, barbotage of bladder and urine
catheterization can be use for getting urine samples.
However, these investigation are rather invasive and less
sensitive investigations compared to histopathological
diagnosis methods. It is necessary to repeat these tests at
certain periods after treatment as there is a strong
possibility that the superficial carcinomas may recur after
operation. Especially in low grade tumors, the diseases
require effective treatment and non-invasive and objective
diagnosis of tests (2,4). The spontaneous urine cytology
is a non-invasive method. However, its sensitivity is about
60% in diagnosing especially low grade UC (11).
Various urinary indicators have been investigated in
order to diagnose and follow up UC. Some of those are
NMP, bladder tumor antigens, receptor of autocrine
motility factor, and fibrinogen destruction factor. M344
and Lewis X, which are urinary cytologic biomarkers, are
known as additional indicators. It has been pointed out
that these indicators can be determined at the initial stage
of tumor or in recurrences (2,3,5).
In previous studies, it has been shown that urine
NMP22 measurements can be used as a non-invasive,
sensitive, objective and qualitative marker, in the
determination of postoperation recurrences of UC (24,8). However, the NMP22 levels are affected by
inflammation, benign urological diseases, age, race,

In our study, the NMP22 levels measured in UC
patients were statistically significantly higher compared to
levels measured in UD and cystitis patients, and in control
group. However, the levels measured in some UC patients
were similar to those of other groups. Due to grey zones
between malignant tumors and other groups, it was
considered that the measurement of NMP22 was not a
good enough criterion to decide the malignancy. The
sensitivity and specificity of this test is not high enough
for the diagnosis of UC.
Additionally, the NMP22 levels of the patients with
different grades of UD initial malignancy, were lower
than those of patients with cystitis. No significant
difference was observed in the NMP22 levels of patients
with dysplasia and cystitis, and control groups. These
results show that determination of NMP22 levels is not a
very useful criterion in diagnosing bladder precancerous
lesions.
It has been reported that NMP22 shows more than
80% (13) or 37-41% (14) false-positive results in
benign inflammatory or infectious diseases, in the
presence of bladder stones, in cases of urinary system
infections, or other genitourinary malignancies.
The conventional method for evaluating initial stage
bladder cancers in the postoperative period is cystoscopic
evaluation or cytologic examination of spontaneous and
catheterized urine or bladder washing water. Urinary
cytology has low sensitivity in low grade papillary and flat
lesions. It also has the risk of not specifying the diagnosis
of invasive lesions. The evaluation of different the same
or pathologists at different times may also be different
(11). Intravesical chemotherapy, radiotherapy and
repetitive catheterization may lead to wrong evaluation of
UC diagnosis by causing changes in exfoliative cells in
urinary infections and kidney stones (2,5).
Soloway et al (5) have reported that the risk of
malignant disease is low if the NMP22 level is lower than
10.0 U/mL, while it is high if the level is higher than 20.0
U/mL. In the last case, cystoscopic examination and
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pathologic evaluation have been suggested. On the other
hand, Stampfer et al (2) reported that the lowest value
for NMP22 is 6.4 U/mL and they suggested that
immediate cystoscopic examination will be necessary if
the levels rise above this critical value.
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In conclusion, urine NMP22 levels are significantly
higher in UC, and its measurement can be used in
examining the recurrences. However, as it can be
increased by other factors, it is better to combine it with
cytologic examinations.
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